Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor Pugh, PhD, FACMG, shared some early highlights from a randomized trial intended to assess the ability of cell-free DNA (cfDNA) sequencing to detect cancers in patients with LFS and similar cancer predisposition syndromes.
Pugh is an associate professor in the University of Toronto Department of Medical Biophysics, senior scientist at the Princess Margaret Cancer Centre, and director of Genomics and senior investigator at the Ontario Institute for Cancer Research. He highlighted this trial as an initiative related to the cfDNA in Hereditary and High-Risk Malignancies (CHARM) Consortium2 in his talk with CancerNetwork, Affirming the Feasibility of cfDNA Sequencing Use in Li-Fraumeni Syndrome
